Amylyx announces formal intention to remove ALBRIOZA from the market
April 04, 2024
Amylyx Pharmaceuticals announced that they have started a process with Health Canada to discontinue the marketing authorization for ALBRIOZA. This means that ALBRIOZA will no longer be available for new patients in Canada. People currently on the therapy in Canada…
Continue reading